Literature DB >> 25741133

Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview.

Luigi Elio Adinolfi1, Riccardo Nevola1, Giacomo Lus1, Luciano Restivo1, Barbara Guerrera1, Ciro Romano1, Rosa Zampino1, Luca Rinaldi1, Ausilia Sellitto1, Mauro Giordano1, Aldo Marrone1.   

Abstract

Hepatitis C virus (HCV) infection is considered a systemic disease because of involvement of other organs and tissues concomitantly with liver disease. Among the extrahepatic manifestations, neuropsychiatric disorders have been reported in up to 50% of chronic HCV infected patients. Both the central and peripheral nervous system may be involved with a wide variety of clinical manifestations. Main HCV-associated neurological conditions include cerebrovascular events, encephalopathy, myelitis, encephalomyelitis, and cognitive impairment, whereas "brain fog", depression, anxiety, and fatigue are at the top of the list of psychiatric disorders. Moreover, HCV infection is known to cause both motor and sensory peripheral neuropathy in the context of mixed cryoglobulinemia, and has also been recently recognized as an independent risk factor for stroke. These extrahepatic manifestations are independent of severity of the underlying chronic liver disease and hepatic encephalopathy. The brain is a suitable site for HCV replication, where the virus may directly exert neurotoxicity; other mechanisms proposed to explain the pathogenesis of neuropsychiatric disorders in chronic HCV infection include derangement of metabolic pathways of infected cells, alterations in neurotransmitter circuits, autoimmune disorders, and cerebral or systemic inflammation. A pathogenic role for HCV is also suggested by improvement of neurological and psychiatric symptoms in patients achieving a sustained virologic response following interferon treatment; however, further ad hoc trials are needed to fully assess the impact of HCV infection and specific antiviral treatments on associated neuropsychiatric disorders.

Entities:  

Keywords:  Hepatitis C virus; Inflammation; Neurological disorders; Psychiatric disorders; Stroke

Mesh:

Substances:

Year:  2015        PMID: 25741133      PMCID: PMC4342902          DOI: 10.3748/wjg.v21.i8.2269

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  152 in total

1.  Severe recurrent myelitis in patients with hepatitis C virus infection.

Authors:  K Marinou Aktipi; S Ravaglia; M Ceroni; R Nemni; M Debiaggi; S Bastianello; E Alfonsi; E Zardini; L Minoli; E Tavazzi; E Marchioni
Journal:  Neurology       Date:  2007-02-06       Impact factor: 9.910

2.  Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.

Authors:  H L Bonkovsky; J M Woolley
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

3.  Activation of brain macrophages/microglia cells in hepatitis C infection.

Authors:  Jeffrey Wilkinson; Marek Radkowski; Jennifer M Eschbacher; Tomasz Laskus
Journal:  Gut       Date:  2010-07-30       Impact factor: 23.059

Review 4.  Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations.

Authors:  Domenico Sansonno; Franco Dammacco
Journal:  Lancet Infect Dis       Date:  2005-04       Impact factor: 25.071

5.  Transverse myelitis associated to HCV infection.

Authors:  Diego Michelon De Carli; Jeferson Pannebeker; Fábio Lopes Pedro; Carlos Jesus Pereira Haygert; Everaldo Hertz; Maristela de Oliveira Beck
Journal:  Braz J Infect Dis       Date:  2009-04       Impact factor: 1.949

6.  Cerebral glucose utilisation in hepatitis C virus infection-associated encephalopathy.

Authors:  Meike Heeren; Karin Weissenborn; Dimitrios Arvanitis; Martin Bokemeyer; Annemarie Goldbecker; Argyro Tountopoulou; Thomas Peschel; Julian Grosskreutz; Hartmut Hecker; Ralph Buchert; Georg Berding
Journal:  J Cereb Blood Flow Metab       Date:  2011-06-01       Impact factor: 6.200

7.  Hepatitis C virus RNA localization in human carotid plaques.

Authors:  Maria Boddi; Rosanna Abbate; Benedetta Chellini; Betti Giusti; Carlo Giannini; Giovanni Pratesi; Luciana Rossi; Carlo Pratesi; Gian Franco Gensini; Laura Paperetti; Anna Linda Zignego
Journal:  J Clin Virol       Date:  2009-11-05       Impact factor: 3.168

Review 8.  A review of sleep disturbance in hepatitis C.

Authors:  Sanjeev Sockalingam; Susan E Abbey; Fahad Alosaimi; Marta Novak
Journal:  J Clin Gastroenterol       Date:  2010-01       Impact factor: 3.062

9.  Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  Clin Ther       Date:  1994 Mar-Apr       Impact factor: 3.393

Review 10.  Human cell types important for hepatitis C virus replication in vivo and in vitro: old assertions and current evidence.

Authors:  Dennis Revie; Syed Zaki Salahuddin
Journal:  Virol J       Date:  2011-07-11       Impact factor: 4.099

View more
  47 in total

1.  Association between dementia and hepatitis B and C virus infection.

Authors:  Hyo Geun Choi; Jae Seung Soh; Jae Sung Lim; Song Yong Sim; Suk Woo Lee
Journal:  Medicine (Baltimore)       Date:  2021-07-23       Impact factor: 1.817

Review 2.  Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection.

Authors:  Iman Ibrahim Salama; Hala M Raslan; Ghada A Abdel-Latif; Somaia I Salama; Samia M Sami; Fatma A Shaaban; Aida M Abdelmohsen; Walaa A Fouad
Journal:  World J Hepatol       Date:  2022-06-27

3.  Impact of hepatitis C virus treatment on the risk of non-hepatic cancers among hepatitis C virus-infected patients in the US.

Authors:  Wei Wang; Vincent Lo Re; Yi Guo; Hong Xiao; Joshua Brown; Haesuk Park
Journal:  Aliment Pharmacol Ther       Date:  2020-09-15       Impact factor: 8.171

Review 4.  Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015.

Authors:  Salvatore Monaco; Sara Mariotto; Sergio Ferrari; Massimiliano Calabrese; Gianluigi Zanusso; Alberto Gajofatto; Domenico Sansonno; Franco Dammacco
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 5.  Hepatitis C virus and neurological damage.

Authors:  Shilu Mathew; Muhammed Faheem; Sara M Ibrahim; Waqas Iqbal; Bisma Rauff; Kaneez Fatima; Ishtiaq Qadri
Journal:  World J Hepatol       Date:  2016-04-28

6.  Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.

Authors:  Vincent Lo Re; Charitha Gowda; Paul N Urick; Joshua T Halladay; Amanda Binkley; Dena M Carbonari; Kathryn Battista; Cassandra Peleckis; Jody Gilmore; Jason A Roy; Jalpa A Doshi; Peter P Reese; K Rajender Reddy; Jay R Kostman
Journal:  Clin Gastroenterol Hepatol       Date:  2016-04-05       Impact factor: 11.382

Review 7.  Rheumatic manifestations of hepatitis C virus chronic infection: Indications for a correct diagnosis.

Authors:  Carlo Palazzi; Emilio D'Amico; Salvatore D'Angelo; Michele Gilio; Ignazio Olivieri
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

8.  Functional MRI and delay discounting in patients infected with hepatitis C.

Authors:  Holly McCready; Milky Kohno; Michael Kolessar; Laura Dennis; Daniel Kriz; Hannah Luber; Renee Anderson; Michael Chang; Anna Sasaki; Kenneth Flora; Arthur Vandenbark; Suzanne H Mitchell; Jennifer M Loftis; William F Hoffman; Marilyn Huckans
Journal:  J Neurovirol       Date:  2018-10-08       Impact factor: 2.643

Review 9.  Fatigue in chronic liver disease patients: prevalence, pathophysiology, and management.

Authors:  Artur Kośnik; Maciej Wójcicki
Journal:  Prz Gastroenterol       Date:  2022-03-18

10.  Prevalence and Odds of Signs of Depression and Anxiety in Patients with Lichen Planus: Systematic Review and Meta-analyses.

Authors:  Isabelle Jalenques; Sophie Lauron; Sebastien Almon; Bruno Pereira; Michel D'Incan; Fabien Rondepierre
Journal:  Acta Derm Venereol       Date:  2020-11-24       Impact factor: 3.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.